Phase 3 N=470 IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Hepatitis C, Chronic
Primary: SVR12 Rates With Historical Control — 82.5; 71.6; 72.5; 72.5 Percentage of participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=9 Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
Lysosomal Acid Lipase Deficiency · Wolman Disease
Primary: Percentage Of Participants In The Primary Efficacy Analysis Set (PES) Surviving To 12 Months Of Age — 67 Percentage of participants
Phase 2 N=13 Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
Prostate Cancer
Primary: Toxicity — 2; 204 events
Phase 3 N=66 Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency
Lysosomal Acid Lipase Deficiency
Primary: Percentage Of Participants Achieving Alanine Aminotransferase Normalization — 31; 7; 56; 37 percentage of participants — p=0.0271
N/A N=55 User Evaluation of the MiniMed 620G and 640G Insulin Pumps
Type 1 Diabetes · Type 2 Diabetes
Primary: User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter — 5.88 units on a scale
N/A N=158 Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants
Phase 2 N=8 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma · Recurrent Adult Liver Carcinoma
Primary: Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 — 0 patients
N/A N=23 Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors
Healthy
Primary: Radlex Scale for Diagnostic Capability Ratings — 3.0610; 3.0633 units on a scale — p=0.415
Phase 4 N=126 Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD
COPD
Primary: Forced Expiratory Volume in 1 Second (FEV1) AUC0-4h After First Dose of Treatment. — 1.7432; 1.7132 Liters*hours — p=0.0250
Phase 4 N=128 Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria
Oral Bacteria Levels in the Mouth
Primary: Anaerobic Bacteria — 8.40; 8.42; 8.43 colony forming units — p=>0.05
Phase 3 N=14,671 Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population) — 9.6; 9.6…
Phase 3 N=372 Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment
Infertility
Primary: Number of Oocytes Retrieved (Per Protocol Population) — 10.8; 10.6 Number of retrieved oocytes — p=0.0003
N/A N=1,168 Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes
Primary: Number of Participants With Adverse Drug Reactions — 13; 4; 1; 1 participants
Phase 2 N=67 Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0) — 7; 2; 40; 42 percentage of participants
Phase 1 N=17 Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Participants With Adverse Events — 3; 4; 10; 2 participants